We are live on ! Find out more
AMLX icon

Amylyx Pharmaceuticals
AMLX

171 hedge funds and large institutions have $1.59B invested in Amylyx Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 62 increasing their positions, 53 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

503% more call options, than puts

Call options by funds: $9.02M | Put options by funds: $1.5M

17% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 53

17% more capital invested

Capital invested by funds: $1.36B → $1.59B (+$230M)

1.02% more ownership

Funds ownership: 102.24% → 103.27% (+1%)

4% less funds holding

Funds holding: 179 → 171 (-8)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

19% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 36

Holders
171
Holders Change
-8
Holders Change %
-4.47%
% of All Funds
2.1%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.06%
New
29
Increased
62
Reduced
53
Closed
36
Calls
$9.02M
Puts
$1.5M
Net Calls
+$7.52M
Net Calls Change
+$2.34M

Top Buyers

1
SL
Siren LLC
Connecticut
+$17.3M
2
Franklin Resources
Franklin Resources
California
+$14.9M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$11M
4
Barclays
Barclays
United Kingdom
+$9.52M
5
JAM
Jupiter Asset Management
United Kingdom
+$8.12M

Top Sellers

1
SI
Sofinnova Investments
California
-$6.37M
2
SCM
Silverarc Capital Management
Massachusetts
-$6.12M
3
Ameriprise
Ameriprise
Minnesota
-$6.07M
4
PSC
Patient Square Capital
California
-$4.23M
5
NCM
Nantahala Capital Management
Connecticut
-$4.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
26
ADAR1 Capital Management
Texas
$13.9M +$1.55M +110,248 +12%
Barclays
27
Barclays
United Kingdom
$13.5M +$9.52M +676,677 +229%
VPM
28
Vanguard Portfolio Management
Pennsylvania
$13.1M +$13.3M +944,781 New
Dimensional Fund Advisors
29
Dimensional Fund Advisors
Texas
$12.5M +$1.86M +131,944 +17%
Connor, Clark & Lunn Investment Management (CC&L)
30
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$12.1M -$1.91M -135,696 -14%
WP
31
Woodline Partners
California
$11.8M +$5.51K +392 +0%
BCM
32
Boxer Capital Management
California
$11.1M – – –
Northern Trust
33
Northern Trust
Illinois
$10.8M -$2.22M -157,856 -17%
Charles Schwab
34
Charles Schwab
California
$9.96M +$45.5K +3,235 +0.5%
Qube Research & Technologies (QRT)
35
Qube Research & Technologies (QRT)
United Kingdom
$9.76M +$4.07M +289,363 +70%
LGM
36
Logos Global Management
California
$9.73M -$3.52M -250,000 -26%
SC
37
Stempoint Capital
New York
$9.31M +$1.47M +104,545 +18%
PHP
38
Parkman Healthcare Partners
Connecticut
$8.64M +$3.37M +239,698 +63%
JAM
39
Jupiter Asset Management
United Kingdom
$8.24M +$8.12M +577,080 +3,705%
VFT
40
Vanguard Fiduciary Trust
Pennsylvania
$8.15M +$8.24M +586,152 New
NCM
41
Nantahala Capital Management
Connecticut
$7.45M -$4.22M -300,000 -36%
RSCM
42
Rock Springs Capital Management
Maryland
$6.95M – – –
Citadel Advisors
43
Citadel Advisors
Florida
$5.72M +$936K +66,564 +19%
Federated Hermes
44
Federated Hermes
Pennsylvania
$5.05M -$1.32M -93,866 -21%
HS
45
HighVista Strategies
Massachusetts
$4.89M +$1.59M +113,273 +47%
CAM
46
Cormorant Asset Management
Massachusetts
$4.87M -$703K -50,000 -13%
UBS Group
47
UBS Group
Switzerland
$4.51M -$3.08M -219,004 -40%
TAM
48
TFG Asset Management
Cayman Islands
$4.42M +$634K +45,049 +17%
IGAM
49
iA Global Asset Management
Quebec, Canada
$4.24M +$4.29M +304,786 New
N
50
Nuveen
North Carolina
$3.68M -$268K -19,051 -7%
1
2
3 4 5

AMLX Hedge Fund Activity: Q1 2026 in Review

171 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q1 2026, worth a combined $1.59B — up 17% from $1.36B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of AMLX and 29 opened new positions — a net loss of 7 holders — while 53 trimmed existing stakes and 62 added.

The largest buyer was Siren LLC, opening a new position worth an estimated $17.3M. The largest seller was Sofinnova Investments, exiting entirely with an estimated $6.37M sold.

  • 171 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q1 2026, down from 179 in Q4 2025.
  • Funds reported $1.59B of Amylyx Pharmaceuticals stock for Q1 2026, up 17% quarter-over-quarter.
  • 29 funds opened new Amylyx Pharmaceuticals positions in Q1 2026 and 36 closed out, a net change of -7 holders.
  • The largest Amylyx Pharmaceuticals buyer in Q1 2026 was Siren LLC, an estimated $17.3M added.
  • The largest Amylyx Pharmaceuticals seller in Q1 2026 was Sofinnova Investments, an estimated $6.37M sold.

Based on aggregated 13F filings for Q1 2026.